Immuron (ASX:IMC)

Executive Summary

Immuron Limited is an Australian biopharmaceutical company specializing in orally delivered polyclonal IgG antibodies derived from hyper-immune bovine colostrum. Its proprietary platform generates pathogen-specific antibodies that act locally in the gastrointestinal tract, targeting enteric infections and inflammatory disorders. Immuron's lead commercial product, Travelan®, is an over-the-counter preventative for traveler's diarrhea caused by enterotoxigenic E. coli (ETEC). The company also has a pipeline targeting Clostridioides difficile infection (CDI) and other GI indications. As a publicly traded company (ASX:IMC), Immuron has established manufacturing and distribution partnerships, generating recurring revenue from Travelan sales. Despite operating in a niche space, the company's technology offers a non-antibiotic approach to GI infections, addressing the growing problem of antimicrobial resistance. Immuron continues to pursue clinical development and commercialization opportunities both domestically and internationally.

Upcoming Catalysts (preview)

• Q4 2026Phase 2/3 results for IMM-124E (C. difficile infection)50% success
• Q2 2027New commercial distribution agreement for Travelan in Asia or Europe40% success
• Q3 2027FDA or TGA approval for expanded indication of Travelan (e.g., pediatric use)30% success